Close Icon
We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Established Jun 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add additional assets to its portfolio. Company founder and CEO Denis Corin describes the progress Q BioMed has made with its first two assets and outlines his ambition to expand further in the coming two to three years.
Q BioMed founder and CEO Denis Corin met Scrip's Mike Ward and provided an update on the company's progress since its founding in June 2015. A biomedical acceleration development company based in New York, the company has now signed two deals, one for an early-stage glaucoma asset and the other for an FDA-approved, first-in-class non-narcotic generic to treat metastatic bone cancer pain that is ready to take to market. Q BioMed is therapeutic area agnostic and is looking to establish a portfolio of hitherto neglected assets from early R&D to commercial-ready, which it will bring to a value inflection point.
He acknowledges that capital is a constraint but points out that the company has derisked itself by acquiring a revenue-ready asset and is now looking to acquire four or five more assets over the next two to three years. These could be from private sources or public companies.
This interview was recorded at EBD Group's Biotech Showcase in San Francisco in January 2017. (Also see " Video Interview: Q BioMed Accelerates Advances In Vascular Therapeutics " - Scrip, 15 Mar, 2016.)
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends.Results from in-depth KOL and payer interviews and physician surveys provide a current understanding of patient segmentation, influences and preferences, prescribing trends, unmet needs, and more
Trialtrove: gold standard clinical trials intelligence
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker: see the drug development process through analysts’ eyes
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.